11:42 PM EDT, 09/09/2026 (MT Newswires) -- Pharmaceuticals company Swedish Orphan Biovitrum (SOBI.ST), or Sobi, said Wednesday that it received the US Food and Drug Administration's fast-track designation for pacritinib to treat Vexas syndrome. Pacritinib is a dual IRAK1/JAK2 inhibitor in phase 2 development. Vexas syndrome is a systemic inflammatory disorder characterized by overlapping hematologic and inflammatory manifestations, with no approved treatments.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.